Results 211 to 220 of about 12,926,306 (256)

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, Volume 6, Issue 10, October 2026.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. [PDF]

Clin Cancer Res
Tran B, Voskoboynik M, Kim SW, Lemech C, Carcereny E, Rha SY, Ahn MJ, Felip E, Lee KH, Castañón Álvarez E, Yang JC, Ascierto PA, Provencio Pulla M, Kondo S, Kuboki Y, Freeman D, Song X, Blando J, Eck S, Song FJ, Tang Z, Kuziora M, Gainer SD, Mitchell P, Asare J, Ayyoub A, Achour I, Subramaniam DS, Im SA.   +28 more
europepmc   +1 more source

Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2160-2170, October 2026.
Objective Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.
Manar Elsayed, Zoe Hsu, Finlay A. McAlister, William D. Leslie, Lisa M. Lix, Sasha Bernatsky, Suzanne N. Morin, Michelle M. Graham, Aurore Fifi‐Mah, Shahin Jamal, Janet Roberts, Carrie Ye   +11 more
wiley   +1 more source

Umbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma. [PDF]

Int J Mol Sci
Zhou Z, Zhu C, Yang Q, Ji C, Ma L, Wang F.   +5 more
europepmc   +1 more source

Pan‐Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling ...
Yingjian Hu, Xinzhu Zeng, Wei Cao, Jianhao Jiao, Yuan Zhao, Jun Wang   +5 more
wiley   +1 more source

Enhancing Anti-CTLA-4 Antibody Delivery to the Brain Using Focused Ultrasound and Microbubbles. [PDF]

Immunotargets Ther
Afonso Pereira M, Drevenakova V, Liu QE, Grewal S, Morse SV.   +4 more
europepmc   +1 more source

The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Cancer genomes shape the immune landscape within the tumor microenvironment (TME), thereby influencing host antitumor immunity. Identifying somatic mutations that modulate the TME is critical for selecting patients most likely to benefit from immunotherapy.
Kyung‐Jin Cho, Byungho Lim
wiley   +1 more source

CTLA-4 and targeted immunotherapy-a key link in the systemic influence of periodontitis: a mini review. [PDF]

Front Dent Med
Thanigaimalai A, Ravindran DM, Balaji SK, Bhuvaneswari B, SriSanjhanaa C.   +4 more
europepmc   +1 more source

Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical location, resulting in diagnosis at ...
Nisha Manav, Akanksha Kashyap, Lakshay Malhotra, Chethan Rajegowda, Chandra Prakash Prasad   +4 more
wiley   +1 more source

CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant <i>Sporothrix</i> spp. Enolase Antigen. [PDF]

Vaccines (Basel)
Momente GJ, Portuondo DL, Deus AF, Curti Gonçalves MR, Piccineli FL, de Oliveira Campos TPC, Téllez-Martínez D, Carlos IZ, Batista-Duharte A.   +8 more
europepmc   +1 more source